Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Abstract Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years ol...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-05-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-025-01297-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850277723100938240 |
|---|---|
| author | Oren Pasvolsky Danai Dima Lei Feng Wenli Dong Tiffany Richards James A. Davis Aimaz Afrough Mariola Vazquez-Martinez Aishwarya Sannareddy Utkarsh Goel Rahul Banerjee Jack Khouri Frances Cervoni Mahmoud R. Gaballa Alex Lieberman-Cribbin Masooma Shifa Rana Kelley Julian Christopher J. Ferreri Leyla Shune Shaun DeJarnette Evguenia Bhurtel Sandra Susanibar Adaniya Andrew Portuguese Hitomi Hosoya Lekha Mikkilineni Gurbakhash Kaur Adriana Rossi Megan M. Herr Daniel Schrum Chenyu Lin Shahzad Raza Yi Lin Shonali Midha Nadeem Omar Shebli Atarsh Joseph McGuirk Douglas Sborov Peter Voorhees Faiz Anwer Melissa Alsina Ciara Freeman Alfred L. Garfall Beatrice M. Razzo Surbhi Sidana Andrew J. Cowan Larry D. Anderson Jr Doris K. Hansen Shambavi Richard Krina K. Patel Hans C. Lee Ariel Grajales-Cruz |
| author_facet | Oren Pasvolsky Danai Dima Lei Feng Wenli Dong Tiffany Richards James A. Davis Aimaz Afrough Mariola Vazquez-Martinez Aishwarya Sannareddy Utkarsh Goel Rahul Banerjee Jack Khouri Frances Cervoni Mahmoud R. Gaballa Alex Lieberman-Cribbin Masooma Shifa Rana Kelley Julian Christopher J. Ferreri Leyla Shune Shaun DeJarnette Evguenia Bhurtel Sandra Susanibar Adaniya Andrew Portuguese Hitomi Hosoya Lekha Mikkilineni Gurbakhash Kaur Adriana Rossi Megan M. Herr Daniel Schrum Chenyu Lin Shahzad Raza Yi Lin Shonali Midha Nadeem Omar Shebli Atarsh Joseph McGuirk Douglas Sborov Peter Voorhees Faiz Anwer Melissa Alsina Ciara Freeman Alfred L. Garfall Beatrice M. Razzo Surbhi Sidana Andrew J. Cowan Larry D. Anderson Jr Doris K. Hansen Shambavi Richard Krina K. Patel Hans C. Lee Ariel Grajales-Cruz |
| author_sort | Oren Pasvolsky |
| collection | DOAJ |
| description | Abstract Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab. Of 385 analyzed patients, 83 (22%) were in the older group (age ≥75) and 302 (78%) in the younger group (age <75). Compared to the younger group, the older group had less adverse baseline disease characteristics, including a lower incidence of high-risk cytogenetics (44.6% vs. 57.9%, p = 0.03) and extramedullary disease (22% vs. 40%, p = 0.02). There were no significant differences in rates of any-grade CRS (52% vs. 59%, p = 0.27), any-grade ICANS (19% vs. 13%, p = 0.12), and overall response rate (62% vs. 53%, p = 0.17) between the older and younger groups. In multivariable analysis, age was not significantly associated with survival outcomes. Our findings suggest that teclistamab is safe and efficacious in well-selected patients ≥75 years old, and advanced age alone should not preclude teclistamab administration. |
| format | Article |
| id | doaj-art-bb9e75e329644a65a362fbe9b28073b4 |
| institution | OA Journals |
| issn | 2044-5385 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-bb9e75e329644a65a362fbe9b28073b42025-08-20T01:49:46ZengNature Publishing GroupBlood Cancer Journal2044-53852025-05-011511610.1038/s41408-025-01297-7Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumOren Pasvolsky0Danai Dima1Lei Feng2Wenli Dong3Tiffany Richards4James A. Davis5Aimaz Afrough6Mariola Vazquez-Martinez7Aishwarya Sannareddy8Utkarsh Goel9Rahul Banerjee10Jack Khouri11Frances Cervoni12Mahmoud R. Gaballa13Alex Lieberman-Cribbin14Masooma Shifa Rana15Kelley Julian16Christopher J. Ferreri17Leyla Shune18Shaun DeJarnette19Evguenia Bhurtel20Sandra Susanibar Adaniya21Andrew Portuguese22Hitomi Hosoya23Lekha Mikkilineni24Gurbakhash Kaur25Adriana Rossi26Megan M. Herr27Daniel Schrum28Chenyu Lin29Shahzad Raza30Yi Lin31Shonali Midha32Nadeem Omar33Shebli Atarsh34Joseph McGuirk35Douglas Sborov36Peter Voorhees37Faiz Anwer38Melissa Alsina39Ciara Freeman40Alfred L. Garfall41Beatrice M. Razzo42Surbhi Sidana43Andrew J. Cowan44Larry D. Anderson Jr45Doris K. Hansen46Shambavi Richard47Krina K. Patel48Hans C. Lee49Ariel Grajales-Cruz50MD Anderson Cancer CenterFred Hutchinson Cancer CenterMD Anderson Cancer CenterMD Anderson Cancer CenterMD Anderson Cancer CenterMedical University of South CarolinaMyeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical CenterMoffitt Cancer CenterMyeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical CenterCleveland Clinic Lerner College of Medicine, Case Western Reserve University School of MedicineFred Hutchinson Cancer CenterCleveland Clinic Lerner College of Medicine, Case Western Reserve University School of MedicineMD Anderson Cancer CenterMD Anderson Cancer CenterMount Sinai School of MedicineStanford UniversityHuntsman Cancer Institute, University of UtahAtrium Health Levine Cancer Institute, Wake Forest University School of MedicineUniversity of Kansas Medical CenterUniversity of Kansas Medical CenterUniversity of Kansas Medical CenterAbramson Cancer Center and Perelman School of Medicine, University of PennsylvaniaFred Hutchinson Cancer CenterStanford UniversityStanford UniversityMyeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical CenterMount Sinai School of MedicineRoswell Park Comprehensive Cancer CenterDuke University Cancer InstituteDuke University Cancer InstituteCleveland Clinic Lerner College of Medicine, Case Western Reserve University School of MedicineDivision of Hematology, Mayo ClinicDana-Farber Cancer InstituteDana-Farber Cancer InstituteAtrium Health Levine Cancer Institute, Wake Forest University School of MedicineUniversity of Kansas Medical CenterHuntsman Cancer Institute, University of UtahAtrium Health Levine Cancer Institute, Wake Forest University School of MedicineCleveland Clinic Lerner College of Medicine, Case Western Reserve University School of MedicineMoffitt Cancer CenterMoffitt Cancer CenterAbramson Cancer Center and Perelman School of Medicine, University of PennsylvaniaAbramson Cancer Center and Perelman School of Medicine, University of PennsylvaniaStanford UniversityFred Hutchinson Cancer CenterMyeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical CenterMoffitt Cancer CenterMount Sinai School of MedicineMD Anderson Cancer CenterMD Anderson Cancer CenterMoffitt Cancer CenterAbstract Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab. Of 385 analyzed patients, 83 (22%) were in the older group (age ≥75) and 302 (78%) in the younger group (age <75). Compared to the younger group, the older group had less adverse baseline disease characteristics, including a lower incidence of high-risk cytogenetics (44.6% vs. 57.9%, p = 0.03) and extramedullary disease (22% vs. 40%, p = 0.02). There were no significant differences in rates of any-grade CRS (52% vs. 59%, p = 0.27), any-grade ICANS (19% vs. 13%, p = 0.12), and overall response rate (62% vs. 53%, p = 0.17) between the older and younger groups. In multivariable analysis, age was not significantly associated with survival outcomes. Our findings suggest that teclistamab is safe and efficacious in well-selected patients ≥75 years old, and advanced age alone should not preclude teclistamab administration.https://doi.org/10.1038/s41408-025-01297-7 |
| spellingShingle | Oren Pasvolsky Danai Dima Lei Feng Wenli Dong Tiffany Richards James A. Davis Aimaz Afrough Mariola Vazquez-Martinez Aishwarya Sannareddy Utkarsh Goel Rahul Banerjee Jack Khouri Frances Cervoni Mahmoud R. Gaballa Alex Lieberman-Cribbin Masooma Shifa Rana Kelley Julian Christopher J. Ferreri Leyla Shune Shaun DeJarnette Evguenia Bhurtel Sandra Susanibar Adaniya Andrew Portuguese Hitomi Hosoya Lekha Mikkilineni Gurbakhash Kaur Adriana Rossi Megan M. Herr Daniel Schrum Chenyu Lin Shahzad Raza Yi Lin Shonali Midha Nadeem Omar Shebli Atarsh Joseph McGuirk Douglas Sborov Peter Voorhees Faiz Anwer Melissa Alsina Ciara Freeman Alfred L. Garfall Beatrice M. Razzo Surbhi Sidana Andrew J. Cowan Larry D. Anderson Jr Doris K. Hansen Shambavi Richard Krina K. Patel Hans C. Lee Ariel Grajales-Cruz Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium Blood Cancer Journal |
| title | Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium |
| title_full | Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium |
| title_fullStr | Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium |
| title_full_unstemmed | Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium |
| title_short | Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium |
| title_sort | outcomes of elderly patients with relapsed refractory multiple myeloma rrmm treated with teclistamab a multicenter study from the u s multiple myeloma immunotherapy consortium |
| url | https://doi.org/10.1038/s41408-025-01297-7 |
| work_keys_str_mv | AT orenpasvolsky outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT danaidima outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT leifeng outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT wenlidong outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT tiffanyrichards outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT jamesadavis outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT aimazafrough outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT mariolavazquezmartinez outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT aishwaryasannareddy outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT utkarshgoel outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT rahulbanerjee outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT jackkhouri outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT francescervoni outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT mahmoudrgaballa outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT alexliebermancribbin outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT masoomashifarana outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT kelleyjulian outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT christopherjferreri outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT leylashune outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT shaundejarnette outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT evgueniabhurtel outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT sandrasusanibaradaniya outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT andrewportuguese outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT hitomihosoya outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT lekhamikkilineni outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT gurbakhashkaur outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT adrianarossi outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT meganmherr outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT danielschrum outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT chenyulin outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT shahzadraza outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT yilin outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT shonalimidha outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT nadeemomar outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT shebliatarsh outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT josephmcguirk outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT douglassborov outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT petervoorhees outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT faizanwer outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT melissaalsina outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT ciarafreeman outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT alfredlgarfall outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT beatricemrazzo outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT surbhisidana outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT andrewjcowan outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT larrydandersonjr outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT doriskhansen outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT shambavirichard outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT krinakpatel outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT hansclee outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium AT arielgrajalescruz outcomesofelderlypatientswithrelapsedrefractorymultiplemyelomarrmmtreatedwithteclistamabamulticenterstudyfromtheusmultiplemyelomaimmunotherapyconsortium |